通过模仿寡类的运输路径来增强SLN的淋巴运输
Fuya Jia1, Xiaoxing Fan1, Licheng Wu1
1Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Asian journal of pharmaceutical sciences
|June 12, 2025
概括
双改性固体脂质纳米颗粒 (SLN) 通过利用寡转运体-1 (PepT-1) 途径来增强口服药物输送. 这种方法可以提高胰岛素和胺类药物的生物可用性和有效性.
科学领域:
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 固体脂质纳米颗粒 (SLN) 提供了通过淋巴运输传递口服蛋白质和药物的潜力.
- 对生物过程至关重要的寡被肠道中的高容量寡载体-1 (PepT-1) 吸收.
- 初步发现表明,通过利用寡类的吸收途径,可以增强SLN运输.
研究的目的:
- 设计和评估二基改性SLN,以改善口服药物输送.
- 研究PepT-1介导的内细胞在SLN吸收中的作用.
- 评估修改后的SLN携带模型类药物的增强口服生物可用性和治疗效果.
主要方法:
- 开发两种类型的双基改造的SLN,封装胰岛素和异化物 (GLP-1类似物).
- 在I型 (C57BL/6) 和II型 (KKAy) 糖尿病小鼠模型中的体内评估.
- 通过PepT-1介导的内细胞和淋巴运输来评估细胞吸收.
主要成果:
- 在糖尿病小鼠中,二胺修饰的SLN显示增强了口服生物可用性和显著的低血糖效应.
- 与未经修改的SLN相比,修改后的SLN通过PepT-1介导的内细胞通过肠上皮细胞表现出更高的内部化.
- 更多的修改后的SLN通过淋巴运输进入了全身循环.
结论:
- 对SLN的二基改造有效地利用PepT-1通路来增强口服药物输送.
- 这一策略显著提高了类药物的生物可用性和治疗疗效.
- 将SLN技术与类载体运输通路相结合,为口服类药物配方提供了一个有前途的方法.
相关概念视频
Carrier-Mediated Transport
313
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
313
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
3.6K
Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
3.6K
Mechanisms of Drug Absorption: Paracellular, Transcellular, and Vesicular Transport
469
Drugs need to permeate cell membranes to reach their target sites after administration. Orally administered drugs must transcend intestinal epithelial membrane barriers to infiltrate the systemic circulation. Drugs with a molecular weight of less than 500 Daltons diffuse through gaps between neighboring cells, called paracellular pathways.
However, most drugs use the transcellular route, traversing directly through the cell membranes via two mechanisms: passive and active transport. Passive...
However, most drugs use the transcellular route, traversing directly through the cell membranes via two mechanisms: passive and active transport. Passive...
469
Delivery Pathways to the Lysosome
6.2K
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
6.2K
Receptor-mediated Endocytosis
104.2K
Overview
104.2K


